Nycomed rides tide of nonionic contrast use

Article

Norwegian contrast developer Nycomed raised $74.7 million lastmonth through a U.S. stock offering. The Oslo firm issued 2.75million American depositary shares at a price of $27.18 a share,according to underwriter Merrill Lynch. The AD shares are listedon

Norwegian contrast developer Nycomed raised $74.7 million lastmonth through a U.S. stock offering. The Oslo firm issued 2.75million American depositary shares at a price of $27.18 a share,according to underwriter Merrill Lynch. The AD shares are listedon the New York Stock Exchange under the symbol HN.

Hafslund Nycomed is a diversified worldwide pharmaceuticalcompany. The company had operating revenues of $855 million in1991 (end-December) and profits of $244 million.

Medical imaging contrast is Nycomed's most profitable businessby far. Last year, $323 million, or 37% of total revenues, werederived from the contrast business. Contrast operating profitsin 1991 were $150 million, or 62% of consolidated operating profits,according to the public offering prospectus.

Nycomed has ridden high on the trend to increased use of nonionicx-ray contrast agents. Omnipaque, Nycomed's nonionic agent, has50% of the North American nonionic x-ray contrast market, whichis the world's largest (see graph). Sterling Winthrop manufacturesand sells Omnipaque in North America under license to Nycomed.

Omnipaque, which uses the active ingredient iohexol, accountsfor 34% of Nycomed's total revenues. Omnipaque sales, both directand through licensees, amounted to over $1 billion last year.The firm introduced its latest nonionic x-ray agent, iopentol-basedImagopaque for vascular applications, at the beginning of thisyear. Nycomed is developing a new nonionic x-ray agent using iodixanol,according to the prospectus.

Nycomed also developed Omniscan, a gadolinium MRI contrastagent currently under FDA application by Sterling. Schering fileda legal complaint against Sterling in U.S. federal court in Delawarein February, alleging that Omniscan infringes on three patentsfor its Magnevist agent. Magnevist is also a gadolinium MRI agentand the only MRI agent approved by the FDA.

The firm has two more MRI agents--for the abdomen and liver--underdevelopment in the clinical testing stage. Much of Nycomed's MRIcontrast technology was obtained through acquisition of U.S. developerSalutar three years ago (SCAN 11/09/88).

Nycomed has also licensed Molecular Biosystems' Albunex ultrasoundcardiac imaging agent for sale in Europe, Africa, the Middle Eastand India.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.